Rethinking how investigator oversight is evidenced in clinical trials

Reimagining how investigator oversight is evidenced ultimately centres around patient outcomes. Every hour an investigator spends on review or sign-off of routine, low-risk data is ostensibly less time spent focusing on the most meaningful, high-value data. This paradigm shift is not just a process improvement, it is both an advancement that emphasises a patient-centric, proportionate, critical-to-quality framework – allowing investigators to focus on the signals that matter most – and encourages oversight that is dynamic, predictive and clinically meaningful, providing the most value for patients.

On a complex clinical trial, an investigator may work through several separate systems to review and sign off on data, often long after it was collected. The resulting record confirms that a review took place but reveals little about the rationale and judgment applied to that review, such as a decision related to eligibility criteria or a lab value recognised as an early sign of toxicity. This reasoning is at the very heart of principal investigator (PI) oversight, but it is not captured through a simple signature.

A better approach would evidence oversight in a way that reflects the clinical and scientific judgment investigators apply in a contemporaneous manner throughout a study”

PI oversight exists to protect participants and ensure integrity and reliability of the data. The science behind trials has moved quickly, and so has the complexity of what investigators are asked to review, while the methods used to document their oversight have largely remained static. A better approach would evidence oversight in a way that reflects the clinical and scientific judgment investigators apply in a contemporaneous manner throughout a study.

How oversight is documented today

Site advisory groups convened through clinical research nonprofit TransCelerate, describe the task of submitting signatures in multiple systems as time consuming, with a single session sometimes taking two to four hours. Much of that signoff happens in batches, often near database lock, and long after the clinical decisions it relates to were made. As such, the current process records an attestation rather than the judgment applied at the time.

As trials become more complex with multiple safety measures, biomarkers, comparators and narrowly segmented populations, it is increasingly important for PIs to focus on the critical-to-quality factors and priority data while having visibility to sponsor quality tolerance limits.

When every data point gets the same sign-off, routine and critical data are treated alike. Repetitive signing pulls attention away from the data and issues that matter most, and makes it harder to distinguish real signals and concerns (eg, important protocol deviations, ineligible patients, dosing errors) in the record. Eligibility decisions may require medical judgment, and this should be a key area of focus – with additional commentary – in the event of concerns related to inclusion/exclusion criteria. When a patient who is not the right fit is enrolled, it can expose that participant to avoidable risk and it may confound the data or result in that patient’s data being excluded from the analysis.

Focusing evidence on critical data and decisions

A risk-proportionate approach to evidencing oversight starts with the critical-to-quality factors identified for a study. These factors often relate to participant safety, protocol adherence, primary endpoints, scientific judgment or the quality and integrity of the data.

Examples of critical data and decisions in those areas often include:

• · Eligibility confirmations
• · Serious adverse events
• · Dose interruptions and reductions
• · Missing data tied to primary endpoints
• · Dosing errors (including protracted/shorter infusion times).

ICH E6(R3) calls for trial processes to be proportionate to the risks to participants and the importance of the data collected, without adding burden for participants or investigators beyond what the trial needs”

Ensuring rigour in these areas translates to the best outcome for patients. Page-by-page signatures on routine or low-risk data, such as an out-of-window assessment with no bearing on an endpoint or on safety, add little assurance or value for patients and the overall trial integrity. ICH E6(R3) calls for trial processes to be proportionate to the risks to participants and the importance of the data collected, without adding burden for participants or investigators beyond what the trial needs.¹ Extending that principle to the evidence of oversight would free more investigator and site time for decisions that call for clinical judgment and give inspectors a more accurate record of how oversight was exercised.

Evidencing oversight as it happens

Many oversight practices have not evolved with advances in technology. Approaches that move data directly from source into a sponsor’s electronic data capture (EDC) system can reduce transcription and duplicate signoff between source documents and electronic case report forms (eCRFs). Many sponsors utilise risk-based quality dashboards to identify data that may require further interrogation/review. Similarly, a data intelligence dashboard for investigators could combine the critical-to-quality factors and areas of highest safety concern for a study, allowing review to happen in real time.

Much of the evidence of oversight is already generated through normal study conduct. Login records, timestamps and audit trails can show that a PI accessed a system and what they entered, changed or marked as reviewed. Strong evidence of oversight also shows that medical judgment was applied. That could be a single dated signoff confirming that protocol deviations and serious adverse events were reviewed up to a given date, noting any actions taken. A focused attestation like that can say more about oversight than a batch of several hundred signatures – many on routine query corrections. Oversight also leaves an evidentiary trail when a PI acts in ways that influence site conduct, whether through questions to sub-investigators, requests for retraining, eligibility clarifications, escalation to the sponsor or initiation of corrective and preventative actions.

A shared view of study risk

Many sponsors already identify risks at the start of a study, set thresholds and quality tolerance limits against them, and track those thresholds through central monitoring. However, sites do not always have visibility of those thresholds or quality tolerance limits. When investigators can see a study’s critical-to-quality factors and the levels a sponsor would consider concerning, sponsors and sites have a shared understanding of risk; investigators can still add areas of focus of their own. For example, if progression-free survival (PFS) censoring rates are a concern in a particular study, sharing the trends or rates across participants that would prompt followup means the investigator is watching for the same signals as the sponsor.

Site-level observations follow a similar pathway. For example, a sponsor might see a cluster of eligibility-related deviations at one site, or earlier-than-expected deaths among participants enrolled under a minimum life-expectancy criterion. Raising those observations with the investigator directly creates a starting point for discussing how oversight of those areas is working.

What adoption will depend on

For investigators, a key open question is how inspectors will view newer ways of evidencing oversight. Shifting away from familiar practice can understandably raise concern about inspection findings. The approaches are intended to be consistent with ICH E6(R3), but sites will look for consistent support from health authorities and inspectors before moving away from familiar practice.

Practical barriers in the systems sites utilise and differences in processes and training may create challenges for adoption. As such, TransCelerate is working to gather input from investigators, sites, contract research organisations (CROs) and technology providers with the aim of reducing the burden on investigators and sites. The intent is to support dialogue across the clinical research ecosystem, including regulators. More efficient processes would benefit everyone involved in running a trial.

Considerations for organisations

Organisations may wish to evaluate several considerations within their current systems and processes to further optimise how PI oversight is evidenced. A key consideration relates to the study-level risks and how these are reflected in site initiation and training, including whether investigators have visibility of the critical-to-quality factors and thresholds from the outset.

Another consideration relates to the investigator’s plan to oversee those factors during the study. An early conversation on this point can show where a site may need support, including any system or resourcing limitations.

Finally, for each area of oversight, sponsors should understand how the review could be evidenced for inspection – whether, for example, through a signature, a dated comment within a system or a log of actions taken.

Another consideration is how central monitoring outputs could become part of an ongoing dialogue with sites, at the study level and where relevant, across a programme or drug class. Each of these brings the evidence of oversight closer to the decisions that shape a trial.

Ultimately, patients are at the heart of clinical research, and freeing investigators to spend more of their time on clinical judgment enables the best outcome for patients.

References

1. ICH harmonised guideline: guideline for good clinical practice E6(R3) [Internet]. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). 2026. [Cited 2026Sep]. Available from: https://database.ich.org/sites/default/files/ICH%20E6%28R3%29_Step4_FinalConsolidatedGuideline_2026_0616_.pdf